Clinical Trials Logo

Recurrent clinical trials

View clinical trials related to Recurrent.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06305299 Not yet recruiting - Ovarian Cancer Clinical Trials

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated. There are two parts to this study. In part 1, approximately blood will be collected from subjects to prepare the iC9.CAR.B7-H3 T cells. The study team will collect disease-fighting T cells from the blood and modify them to prepare the iC9.CAR.B7-H3 T cells. In part 2, the iC9.CAR.B7-H3 T cells will be given to eligible subjects by infusion three days after completion of lymphodepletion chemotherapy.

NCT ID: NCT05807984 Not yet recruiting - Rectal Cancer Clinical Trials

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

Prospective phase II clinical study aim to explore the clinical outcome of patients with unresectable locally recurrent rectal cancer (LRRC) treated with re-irradiation by carbon ion radiotherapy (CIRT)

NCT ID: NCT04599452 Not yet recruiting - Elderly Clinical Trials

NK Cell Therapy Recurrent/Refractory Elderly AML

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.